The median progression-free survival among patients with low tumor CcO activity was 9.75 months (95% CI, 8.47 to 14.30), as compared with 5.5 months (95% CI, 2.72 to 5.74) among patients with high tumor CcO activity (P = 0.0087 by the log-rank test) (Figure 2D). Here, RYR1 is linked to neoplasm.